See more : Roland Corporation (7944.T) Income Statement Analysis – Financial Results
Complete financial analysis of Pluri Inc. (PLUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluri Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Medacta Group SA (0A05.L) Income Statement Analysis – Financial Results
- PT Midi Utama Indonesia Tbk (MIDI.JK) Income Statement Analysis – Financial Results
- Daewon Pharmaceutical Co., Ltd. (003220.KS) Income Statement Analysis – Financial Results
- Automobile & PCB Inc. (015260.KS) Income Statement Analysis – Financial Results
- Abrdn Global Dynamic Dividend Fund (AGD) Income Statement Analysis – Financial Results
Pluri Inc. (PLUR)
About Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.00K | 287.00K | 234.00K | 0.00 | 23.00K | 54.00K | 50.00K | 0.00 | 2.85M | 379.00K | 379.00K | 679.00K | 716.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00K | 9.00K | 41.59M | 50.62M | 1.57M | 2.00K | 2.00K | 2.18M | 100.00K | 13.00K | 11.00K | 20.00K | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K |
| Gross Profit | 322.00K | 278.00K | -41.36M | -50.62M | -1.55M | 52.00K | 48.00K | -2.18M | 2.75M | 366.00K | 368.00K | 659.00K | 695.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.00K |
| Gross Profit Ratio | 98.77% | 96.86% | -17,674.79% | 0.00% | -6,726.09% | 96.30% | 96.00% | 0.00% | 96.49% | 96.57% | 97.10% | 97.05% | 97.07% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.45M | 15.75M | 24.38M | 30.07M | 21.58M | 26.43M | 22.63M | 21.09M | 19.58M | 19.17M | 19.54M | 17.23M | 9.18M | 6.63M | 4.30M | 3.14M | 4.39M | 2.55M | 1.30M | 1.79M | 1.22M | 79.87K | 0.00 |
| General & Administrative | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.96K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.66K | 0.00 |
| SG&A | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 3.42M | 6.04M | 3.73M | 1.03M | 873.65K | 1.78M | 130.62K | 74.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.62K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.48M | 27.52M | 41.83M | 50.62M | 29.50M | 35.58M | 33.78M | 28.02M | 26.07M | 25.63M | 28.22M | 22.88M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Cost & Expenses | 22.48M | 27.53M | 41.83M | 50.62M | 29.50M | 35.59M | 33.78M | 28.02M | 26.17M | 25.65M | 28.23M | 22.90M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Interest Income | 1.31M | 1.08M | 581.00K | 492.00K | 384.00K | 385.00K | 276.00K | 122.00K | 149.00K | 112.00K | 246.00K | 266.00K | 575.00K | 236.00K | 2.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 866.00K | 843.00K | 887.00K | 78.00K | 196.00K | 29.00K | 937.00K | 0.00 | 100.00K | 37.00K | 36.00K | 29.00K | 12.00K | 13.00K | 31.00K | 8.00K | 0.00 | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 3.45K |
| Depreciation & Amortization | 253.00K | 362.00K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M | 2.15M | 2.07M | 1.90M | 1.03M | 435.00K | 312.00K | 207.00K | 173.00K | 129.00K | 224.72K | 264.83K | 202.85K | 153.64K | 21.04K | 0.00 |
| EBITDA | -20.23M | -27.68M | -39.43M | -48.42M | -27.39M | -33.35M | -24.05M | -25.57M | -21.01M | -22.57M | -25.03M | -21.19M | -14.35M | -10.52M | -7.23M | -6.51M | -10.35M | -7.42M | -2.10M | -1.87M | -1.84M | 0.00 | -74.45K |
| EBITDA Ratio | -6,203.99% | -8,995.12% | -17,087.18% | 0.00% | -119,800.00% | -61,924.07% | -79,958.00% | 0.00% | -743.06% | -6,255.41% | -7,033.25% | -3,081.59% | -2,003.77% | 644.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.16M | -27.25M | -41.59M | -50.62M | -29.48M | -35.53M | -33.73M | -28.02M | -23.32M | -25.27M | -27.85M | -22.22M | -15.03M | -11.11M | -7.44M | -6.56M | -10.43M | -6.28M | -2.33M | -2.83M | -3.00M | -456.96K | -74.45K |
| Operating Income Ratio | -6,796.93% | -9,493.38% | -17,774.79% | 0.00% | -128,156.52% | -65,800.00% | -67,462.00% | 0.00% | -819.07% | -6,666.75% | -7,348.28% | -3,272.90% | -2,099.30% | 660.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.00K | -1.64M | 219.00K | 758.00K | 324.00K | 225.00K | 7.61M | 205.00K | 73.00K | 590.00K | 918.00K | 1.07M | 237.00K | 266.00K | -14.00K | -84.00K | -69.00K | -2.15M | -107.46K | 731.65K | 994.18K | 0.00 | 0.00 |
| Income Before Tax | -21.34M | -28.89M | -41.37M | -49.87M | -29.15M | -35.31M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -11.07M | -7.46M | -6.64M | 0.00 | -8.24M | 0.00 | -2.09M | 0.00 | 418.26K | 0.00 |
| Income Before Tax Ratio | -6,547.24% | -10,065.16% | -17,681.20% | 0.00% | -126,747.83% | -65,383.33% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 658.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 277.00K | -351.00K | 78.00K | 196.00K | -94.00K | 7.61M | -205.00K | -73.00K | -590.00K | -918.00K | 29.00K | 249.00K | -266.00K | 14.00K | 78.00K | 69.00K | 2.15M | 107.46K | -731.65K | -994.17K | 252.51K | 77.90K |
| Net Income | -20.89M | -28.32M | -41.02M | -49.94M | -29.35M | -35.21M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -10.85M | -7.45M | -6.64M | -10.50M | -8.43M | -2.44M | -2.10M | -2.01M | -463.00K | -77.90K |
| Net Income Ratio | -6,407.36% | -9,867.94% | -17,531.20% | 0.00% | -127,600.00% | -65,209.26% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 644.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| EPS Diluted | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| Weighted Avg Shares Out | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
| Weighted Avg Shares Out (Dil) | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Memorandum of Understanding has been signed NEW YORK , Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU)...
Plurilock Corporate Update for Shareholders
CEO Ian L. Paterson will host a webinar and Q&A Tuesday July 23, 2024, at 1pm ET / 10am PT Announced over $20 million of new business since the beginning of the year Growth in Critical Services business driving margin...
Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates
PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies PluriCDMO™, the Company's contract development and manufacturing organization, recognized as a...
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri's subsidiary, Ever...
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract
HAIFA, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the...
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced a strategic collaboration with Wilk Technologies...
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
HAIFA, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the “Company”), a leading biotechnology company that transforms cells into solutions, today launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors –...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells...
Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries Pluri's business verticals leverage Company's world-leading 3D cell expansion know-how, IP, and manufacturing facility to...
Source: https://incomestatements.info
Category: Stock Reports